- Visibility8
- Citations0
- Sentiment100
- Site quality87
- AI readiness14
AI assistants rarely name Monopar Therapeutics, mentioning it in 1 of 60 answers, which is less often than usual for this sector. Its overall score is 38 out of 100, ranking 609th of 2,047 companies and 15th of 105 in Healthcare. The Monopar Therapeutics website passes 2 of 14 technical checks for AI tool readiness.
We asked 15 unbranded questions about the healthcare market: none named Monopar Therapeutics. AI assistants named it in 1 of 60 answers (1.7%). The typical healthcare company is named in 3.3% of answers. By how often it is named, Monopar Therapeutics ranks 56 of 105 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
An answer that names the company
“Which investigational treatments are showing the most potential for Wilson Disease right now?”
Based on recent data, several investigational treatments for Wilson Disease show significant promise:
Gene Therapies
A growing pipeline of investigational therapies is reshaping expectations for future Wilson disease management, with multiple gene-based and next-generation approaches that aim to restore ATP7B function at the hepatocyte level, using strategies that include AAV gene transfer, mini-gene constructs, and emerging gene-editing platforms.
VTX-801 (Vivet Therapeutics): The ongoing phase 1/2 GATEWAY trial is evaluating safety, tolerability, and preliminary efficacy of escalat …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 0: Not yet agent-ready. Agents struggle to find basic information about the site.
- 2 of robots.txt, Sitemap, Link headers
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtNot met
Publish a valid robots.txt with crawl rules and a Sitemap line.
- study: 86.8%SitemapPartly met
Serve an XML sitemap and reference it from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesNot met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 7 of 100 · 97% of checks could run · checked on October 5, 2026 · www.monopartx.com · 2,047 companies scanned
2 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Not metrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- Not metHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
How many times each website was listed as a source in these answers
In the study as US-listed.
- How do radiopharmaceutical treatments compare to traditional chemotherapy for late-stage cancer?
- Are there new non-copper chelating agents for Wilson Disease under clinical development?
- How can treatment resistance develop with investigational therapies for rare genetic diseases?
- What are the most promising targeted radiopharmaceutical therapies for solid tumors currently in clinical trials?
- What should healthcare institutions expect in terms of cost when adopting novel targeted cancer therapies?
- Who would benefit from emerging therapies designed for genetic disorders like Wilson Disease?
- Is it worthwhile to participate in clinical trials for new Wilson Disease therapies?
- Are next-generation radiopharmaceuticals for advanced cancers worth considering for patients refractory to standard therapies?
- What are some alternatives to radiopharmaceuticals for treating advanced-stage solid tumors?
- What are common side effects seen in patients receiving radiopharmaceuticals for cancer therapy?
- How are investigational radiopharmaceutical therapies typically priced in the US market?
- Which investigational treatments are showing the most potential for Wilson Disease right now?
- What advancements are being made in personalized therapeutics for rare diseases in the US?
- Radiopharmaceuticals vs immunotherapy: which offers better outcomes in oncology cases?
- In what scenarios would a healthcare provider consider novel imaging agents for solid tumor diagnosis?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.